Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes

Experimental and Therapeutic Medicine

Volumn 8, Issue 3, 2014, Pages 951-956

  Hu, Zhi Juan ^a   Ren, Lu Ping ^a   Wang, Chao ^a   Liu, Bing ^a   Song, Guang Yao ^a  

^a HEBEI GENERAL HOSPITAL   (China)

Author keywords

Apolipoprotein CIII; Diabetic nephropathy; Microalbuminuria; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN C3; ATORVASTATIN; EDETIC ACID; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ELEVATED BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FASTING BLOOD GLUCOSE; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INTERVIEW; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RETINOPATHY; RISK; SYSTOLIC BLOOD PRESSURE;

EID: 84904393388     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1830     Document Type: Article

References (31)

1. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH and Steffes MW; American Diabetes Association: Nephropathy in diabetes. Diabetes Care 27 (Suppl 1): S79-S83, 2004.
2. Ravid M, Brosh D, Ravid-Safran D, Levy Z and Rachmani R: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158: 998-1004, 1998.
3. Hirano T: Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl 71: S22-S24, 1999.
4. Boyle KE, Phillips MC and Lund-Katz S: Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. Biochim Biophys Acta 1430: 302-312, 1999.
5. Breyer ED, Le NA, Li X, Martinson D and Brown WV: Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size. J Lipid Res 40: 1875-1882, 1999.
6. Jong MC, Hofker MH and Havekes LM: Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19: 472-484, 1999.
7. Campos H, Perlov D, Khoo C and Sacks FM: Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 42: 1239-1249, 2001.
8. Davidsson P, Hulthe J, Fagerberg B, Olsson BM, Hallberg C, Dahllöf B and Camejo G: A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res 46: 1999-2006, 2005.
9. Schonfeld G, George PK, Miller J, Reilly P and Witztum J: Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism 28: 1001-1010, 1979.
10. Talmud PJ and Humphries SE: Apolipoprotein C-III gene variation and dyslipidaemia. Curr Opin Lipidol 8: 154-158, 1997.
11. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA and Braunwald E: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102: 1886-1892, 2000.
12. Lee SJ, Campos H, Moye LA and Sacks FM: LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 23: 853-858, 2003.
13. Ginsberg HN, Le NA, Goldberg IJ, Gibson JC, Rubinstein A, Wang-Iverson P, Norum R and Brown WV: Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 78: 1287-1295, 1986.
14. Ebara T, Ramakrishnan R, Steiner G and Shachter NS: Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest 99: 2672-2681, 1997.
15. Sehayek E and Eisenberg S: Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 266: 18259-18267, 1991.
16. Jong MC, Hofker MH and Havekes LM: Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 19: 472-484, 1999.
17. Shachter NS: Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 12: 297-304, 2001.
18. Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D and Brown WV: Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 49: 167-177, 2000.
19. Friedewald WT, Levy RI and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972.
20. Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998.
21. Genuth SM: The case for blood glucose control. Adv Intern Med 40: 573-623, 1995.
22. Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352: 213-219, 1998.
23. Brunzell JD and Ayyobi AF: Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 115 Suppl 8A: S24-S28, 2003.
24. Batal R, Tremblay M, Barrett PH, Jacques H, Fredenrich A, Mamer O, Davignon J and Cohn JS: Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 41: 706-718, 2000.
25. Barr SI, Kottke BA and Mao SJ: Postprandial exchange of apolipoprotein C-III between plasma lipoproteins. Am J Clin Nutr 34: 191-198, 1981.
26. Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, Lyons TJ and Garvey WT; DCCT/EDIC Research Group: Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications 19: 18-25, 2005.
27. Davidson M: A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol 102: 19L-27L, 2008.
28. Takemoto M and Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001.
29. Dallongeville J, Fruchart JC, Maigret P, Bertolini S, Bon GB, Campbell MM, Farnier M, Langan J, Mahla G, Pauciullo P and Sirtori C: Double-blind comparison of apolipoprotein and lipoprotein particle lowering effects of atorvastatin and pravastatin monotherapy in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 3: 103-110, 1998.
30. Rutter MK, Prais HR, Charlton-Menys V, Gittins M, Roberts C, Davies RR, Moorhouse A, Jinadev P, France M, Wiles PG, Gibson JM, Dean J, Kalra PA, Cruickshank JK and Durrington PN: Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high-vs. low-dose atorvastatin. Diabet Med 28: 100-108, 2011.
31. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53: 766-772, 2007